susoctocog alfa

Susoctocog alfa is a recombinant, B-domain deleted, porcine sequence antihaemophilic factor VIII (FVIII) product used to treat and control bleeding episodes in adults with acquired haemophilia A. Acquired haemophilia A is a rare disorder where patients develop autoantibodies that neutralize endogenous human factor VIII, leading to impaired blood clotting. Susoctocog alfa acts as a replacement for the inhibited human FVIII; its porcine sequence makes it less susceptible to neutralization by these antibodies. By restoring FVIII activity in the coagulation cascade—specifically facilitating the activation of factor X and subsequent thrombin generation—it enables normal clot formation and hemostasis. The drug is administered intravenously and has demonstrated efficacy in clinical trials for rapid control of bleeding episodes[1][2][4][6][8].

Brand names

Obizur

Other names

recombinant porcine factor VIIIrpFVIIIantihaemophilic factor VIII (porcine sequence)